Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,596 |
Ending reported balance
After 2026-08-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 21,132 · Balance 52,728 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 12,429 · Balance 65,157 Row 3 · 2026-08-25 · Sale · Disposed 33,561 · Balance 31,596 F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 7,044 |
Reported balance
After 2026-08-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-25 · Exercise / conversion · Disposed 21,132 · Balance 7,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 12,429 |
Reported balance
After 2026-08-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-25 · Exercise / conversion · Disposed 12,429 · Balance 12,429 |
| Common StockSEC Table I · non-derivative | Indirect2024 GRAT | 5,423 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,423 |
| Common StockSEC Table I · non-derivative | Indirect2025 GRAT | 10,780 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,780 |
| Common StockSEC Table I · non-derivative | Indirect2026 GRAT | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 155,611 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 155,611 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust Held By Spouse | 10,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.59 | $12,658.50 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,385 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $126.58 | $37,974.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,485 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.57 | $12,656.50 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,785 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.53 | $12,653.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,885 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.50 | $12,650.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,985 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $126.49 | $25,298.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,085 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 493 | $126.48 | $62,354.64 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,285 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.46 | $12,645.50 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,778 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $126.44 | $63,220.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,878 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.41 | $12,640.50 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,378 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 8 | $126.39 | $1,011.12 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,478 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.38 | $12,637.50 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,486 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.36 | $12,636.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,586 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.35 | $12,635.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,686 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $126.34 | $25,268.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,786 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $126.32 | $37,896.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,986 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $126.31 | $25,262.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,286 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $126.28 | $63,140.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,486 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.27 | $12,627.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,986 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 7 | $126.26 | $883.82 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,086 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.25 | $12,625.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,093 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $126.24 | $37,872.00 |
DisclosureSEC source: 0001127602-18-036005 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,193 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 201 | $127.30 | $25,586.30 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 24 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,084 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $127.28 | $38,184.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 23 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,285 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $127.25 | $25,450.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,585 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $127.22 | $12,722.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,785 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $127.21 | $12,721.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,885 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $127.20 | $25,439.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,985 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $127.19 | $63,595.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,185 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $127.17 | $25,434.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,685 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $127.16 | $12,716.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,885 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $127.13 | $12,713.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,985 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $127.12 | $12,712.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,085 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $127.10 | $25,420.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,185 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $127.09 | $25,418.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,385 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $127.06 | $12,706.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,585 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $127.05 | $25,409.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,685 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $127.01 | $25,402.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,885 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $126.99 | $25,398.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,085 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.98 | $12,698.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,285 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $126.93 | $25,386.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,385 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.92 | $12,692.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,585 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $126.90 | $25,380.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,685 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $126.87 | $25,374.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,885 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 80 | $126.85 | $10,148.00 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,085 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 39 | $126.84 | $4,946.76 |
DisclosureSEC source: 0001127602-18-035998 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,165 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 25,123 | $0.00 Strike: $73.70 | $0.00 |
DisclosureSEC source: 0001127602-18-035994 · form4.xml · derivative · entry 29 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,247 Underlying: Common Stock · 25,123 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 201 | $126.20 | $25,366.20 |
DisclosureSEC source: 0001127602-18-035994 · form4.xml · nonDerivative · entry 25 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,493 F3 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4 | $126.20 | $504.78 |
DisclosureSEC source: 0001127602-18-035994 · form4.xml · nonDerivative · entry 24 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,694 F3 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $126.18 | $12,618.00 |
DisclosureSEC source: 0001127602-18-035994 · form4.xml · nonDerivative · entry 23 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,698 F3 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.